Aleksandra Syguła

OC7.1 - ECE_2484 - Pancreatic neuroendocrine neoplasms share germline DNA repair gene predisposition with breast, ovarian and colorectal cancer syndromes (BRCA2, CHEK2 and MMR)

Beata Jurecka‐Lubieniecka, Małgorzata Roś-Mazurczyk, Aleksandra Syguła, Alexander Cortez et autres

Abstract Mutations in DNA repair genes are major drivers of both hereditary and sporadic malignancies, including breast, ovarian, prostate, colorectal adenocarcinoma, and pancreatic cancer. Familial tumors are typically associated with earlier onset and a more aggressive clinical phenotype. Advances in diagnostics and …

pl (code pays fourni par la source)

EP905 - ECE_3681 - The picture of adrenocortical carcinoma recurrence upon mitotane in adjuvant setting in a cohort from Central Europe Center

Agnieszka Kotecka-Blicharz, Kornelia Hasse-Lazar, Jordi Gras-Ozimek, Alexander Cortez et autres

Abstract As adrenocortical carcinomais the malignancy known for its preponderance to relapse, adjuvate therapy is a crucial issue in patient management.The clinical justification for the use of adjuvant therapy is to reduce the risk of local and distant recurrenceand/or improve survival. Mitotane …

hu, pl (code pays fourni par la source)

Germline Mutations in DNA Repair Genes in Patients with Pancreatic Neuroendocrine Neoplasms: Diagnostic and Therapeutic Implications

Beata Jurecka‐Lubieniecka, Małgorzata Roś-Mazurczyk, Aleksandra Syguła, Alexander Jorge Cortez et autres

Pancreatic neuroendocrine neoplasms (pNENs) are the second most common type of pancreatic cancer after pancreatic ductal adenocarcinoma. Germline mutations in DNA repair genes drive several hereditary and sporadic cancers; however, their role in pNENs remains poorly defined. This pilot study aimed to …

pl, hu (code pays fourni par la source)

Recurrence patterns in differentiated thyroid cancer (DTC) following adjuvant radioiodine therapy

Aleksandra Ledwoń, Aleksandra Kropińska, Ewa Paliczka-Cieślik, Aleksandra Blewąska et autres

INTRODUCTION: With an increasing incidence of differentiated thyroid cancer (DTC) diagnosis, questions emerge about the optimal duration of follow-up for detecting recurrent disease and its outcomes. The objective of this retrospective research was to assess the clinical course of differentiated thyroid cancer …

hu, pl (code pays fourni par la source)

Prospective, observational study on radioiodine treatment in DTC patients with intermediate RISK or micro lymph node metastases

Aleksandra Blewąska, Aleksandra Ledwoń, Ewa Paliczka-Cieślik, Aleksandra Syguła et autres

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

Aleksandra Syguła, Aleksandra Ledwoń, Kornelia Hasse-Lazar, Beata Jurecka‐Lubieniecka et autres

pl (code pays fourni par la source)

In Patients With Well-Differentiated Neuroendocrine Tumours, There Is No Apparent Benefit of Somatostatin Analogues After Disease Control By Peptide Receptor Radionuclide Therapy

Aleksandra Syguła, Aleksandra Ledwoń, Kornelia Hasse-Lazar, Beata Jurecka‐Lubieniecka et autres

Abstract Purpose Peptide receptor radionuclide therapy (PRRT) and somatostatin analogues (SSAs) are commonly combined as primary treatment for neuroendocrine neoplasm (NEN), and SSAs given as maintenance treatment. We sought to evaluate whether sequential therapy with PRRT followed by SSAs has progression or …

hu (code pays fourni par la source)

Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer

Aleksandra Ledwoń, Ewa Paliczka-Cieślik, Aleksandra Syguła, Tomasz Olczyk et autres

Abstract Objective In patients with differentiated thyroid carcinoma (DTC), serum thyroglobulin levels measured at the time of remnant ablation after thyroid hormone withdrawal were shown to have prognostic value for disease-free status. We sought to evaluate serial thyroglobulin measurements at the time …

hu, pl (code pays fourni par la source)

Treatment with somatostatin analogues after radiopeptide therapy

Daria Handkiewicz-Junak, Aleksandra Syguła, Beata Jurecka‐Lubieniecka, Kornelia Hasse-Lazar et autres

pl (code pays fourni par la source)

Rekomendacje Polskich Towarzystw Naukowych „Diagnostyka i leczenie raka tarczycy”. Aktualizacja na rok 2018

Barbara Jarząb, Marek Dedecjus, Dorota Słowińska-Klencka, Andrzej Lewiñski et autres

Significant advances have been made in thyroid can-cer research in recent years, therefore relevant clinical guidelines need to be updated. The current Polish guidelines "Diagnostics and Treatment of Thyroid Carcinoma" have been formulated at the "Thyroid Cancer and Other Malignancies of Endocrine …

pl, es, my (code pays fourni par la source)

The risk of thyroid cancer (TC) in a thyroid nodule on the basis of a tertiary reference TC center experience

Aleksandra Blewąska, Aleksandra Syguła, Ewa Chmielik, Ewa Stobiecka et autres

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Consolidation treatment with somatoatatin analogues after radiopeptide therapy

Aleksandra Syguła, Daria Handkiewicz-Junak, Agnieszka Kotecka-Blicharz, Kornelia Hasse-Lazar et autres

Although neuroendocrine tumours (NET) constitute a very heterogeneous group, most of them express somatostatin receptors that enable treatment with somatostatin analogues, which proved to be effective both as bio-or radiopeptide therapy.However, little is now about combining this two treatment modalities.The aim of …

pl (code pays fourni par la source)